Retrospective Analysis of 50 Cases of First Allogeneic Transplantation for Acute Myelogenous Leukemia and High Risk Myelodysplastic Syndrome

DOI Web Site Web Site 28 References Open Access
  • ANDO Toshihiko
    Endocrinology, Metabolism, Hematological Sciences and Therapeutics (Internal Medicine III.), Yamaguchi University Graduate School of Medicine
  • NAKAMURA Yukinori
    Endocrinology, Metabolism, Hematological Sciences and Therapeutics (Internal Medicine III.), Yamaguchi University Graduate School of Medicine
  • NAWATA Ryohei
    Endocrinology, Metabolism, Hematological Sciences and Therapeutics (Internal Medicine III.), Yamaguchi University Graduate School of Medicine
  • TAKAHASHI Toru
    Endocrinology, Metabolism, Hematological Sciences and Therapeutics (Internal Medicine III.), Yamaguchi University Graduate School of Medicine
  • MITANI Noriyuki
    Endocrinology, Metabolism, Hematological Sciences and Therapeutics (Internal Medicine III.), Yamaguchi University Graduate School of Medicine
  • YAMASHITA Koji
    Endocrinology, Metabolism, Hematological Sciences and Therapeutics (Internal Medicine III.), Yamaguchi University Graduate School of Medicine
  • TANAKA Yoshinori
    Endocrinology, Metabolism, Hematological Sciences and Therapeutics (Internal Medicine III.), Yamaguchi University Graduate School of Medicine
  • TANAKA Mayumi
    Endocrinology, Metabolism, Hematological Sciences and Therapeutics (Internal Medicine III.), Yamaguchi University Graduate School of Medicine
  • ARIYOSHI Koichi
    Endocrinology, Metabolism, Hematological Sciences and Therapeutics (Internal Medicine III.), Yamaguchi University Graduate School of Medicine
  • NOMIYAMA Jun
    Endocrinology, Metabolism, Hematological Sciences and Therapeutics (Internal Medicine III.), Yamaguchi University Graduate School of Medicine
  • TSURU Masatoshi
    Endocrinology, Metabolism, Hematological Sciences and Therapeutics (Internal Medicine III.), Yamaguchi University Graduate School of Medicine
  • YUJIRI Toshiaki
    Endocrinology, Metabolism, Hematological Sciences and Therapeutics (Internal Medicine III.), Yamaguchi University Graduate School of Medicine
  • TANIZAWA Yukio
    Endocrinology, Metabolism, Hematological Sciences and Therapeutics (Internal Medicine III.), Yamaguchi University Graduate School of Medicine

Bibliographic Information

Other Title
  • 急性骨髄性白血病，ハイリスク骨髄異形成症候群に対する初回同種移植５０症例の後方視的解析
  • キュウセイ コツズイエン ハッケツビョウ ハイリスク コツズイ イケイセイ ショウコウグン ニ タイスル ショカイ ドウシュ イショク 50ショウレイ ノ コウホウシテキ カイセキ
  • キュウセイ コツズイセイ ハッケツビョウ ハイリスク コツズイイケイセイ ショウコウグン ニ タイスル ショカイ ドウシュ イショク 50 ショウレイ ノ コウホウ シテキ カイセキ

Search this article

Abstract

In this single center retrospective study, we studied 50 adults with acute myelogeneous leukemia (AML)(n=40) and myelodysplastic syndrome (MDS)(n=10) who received first allogeneic hematopoietic stem cell transplantation (allo-HSCT) to determine pre-transplant prognostic factors. The median age of our patients was 41. 4 years. Thirty two per cent of the patients were transplanted in non-remission and 44% have poor risk chromosomal abnormalities by National Comprehensive Cancer Network (NCCN) for AML and international prognostic scoring system (IPSS) for MDS. At 3 years, probabilities of overall survival, progression free survival, relapse rate and non-relapse mortality rate were 48.8, 41.3, 38.9 and 27.8% for the whole cohort, respectively. The prognostic impact for several pre-transplant parameters was assessed by univariate and by multivariate analyses using the Cox regression model. As a result, we reached conclusions that poor risk chromosomal abnormality was the most important prognostic factor before transplantation. We divided a chromosomal risk into a group of good plus intermediate risk (good risk group) and a group of poor risk (poor risk group) and performed analysis. We obtained conclusions to consider by therapeutic stratification in a chromosome risk in allo-HSCT as well as chemotherapy.

Journal

References(28)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top